Vericel Corporation
$40.02
-$0.01 (-0.02%)
$39.56Day Range$40.21
Key Statistics
Market Cap
$2.05B
Shares Outstanding
51.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 4, 1997
Round Lot
100
Locale
US
Trading Data
Day Open
$39.80
Day High
$40.21
Day Low
$39.56
Volume
1.13M
VWAP
$39.96
Prev Close
$40.03
Transactions
--
Acc. Volume
--
About Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836398 employees25 BLUE SKY DRIVE, BURLINGTON, MA, 01803(617) 588-5555IPO Feb 4, 1997US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000887359
- Composite FIGI
- BBG000BDCM24
- Share Class FIGI
- BBG001S6X9M3
- Ticker Root
- VCEL
- SIC Code
- 2836
About Vericel Corporation (VCEL) Stock
Vericel Corporation (VCEL) closed the 2026-09-18 session at $40.02, down 0.02% versus the previous close (-0.01). The stock opened at $39.80 and traded between $39.56 and $40.21 during that session. Session trading volume was 1.1M shares. The volume-weighted average price (VWAP) is $39.96.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Vericel Corporation has a market capitalization of $2.05 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. VCEL is listed on the XNAS exchange. The company employs approximately 398 people. Vericel Corporation is headquartered in BURLINGTON, MA. The recorded listing date is 1997-02-04.
On this page you can find market VCEL stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.